## Index

### A

Access to Information and Privacy (ATIP) requests. See Canada, FOI requests in AdisInsight 89–92
Advisory Committee (AdCom) profiles
- committee chair 115–124
- non-voting industry representative 116
online publications/services 122
profile process 114
public hearing speakers 116
resources for 121
sources for profile information 113
temporary voting members 116–124
Agencia Nacional de Vigilancia Sanitaria (ANVISA)
- organizational structure of 9
- overview 9
alert services
- automatic alerts from databases 82
- for surveillance and monitoring 48
- Google Alerts 49
- Talkwalker Alerts 49
artificial intelligence 179
- competitive edge from 180–185
- compliance and quality control 184–185
curation and annotation of data 182–185
data analysis 183–185
data collection 181–185
data ingestion 182–185
future of 184
- monitoring technologies for RI 181
- storage and searching data 183
technologies and uses 179–185
audience
- format of research output and 58
- for newsletters 157
- for white papers 98–100
Australia, FOI requests in
- appeal of denial 107–110
- information available with 106–110
- information released by TGA 107
- refusal of request or redaction 107
- request processing 106–110
- submission of request 106–110
- timeline for processing 106
- use of FOI vendors 107

### B

background for work in RI 24
Biomedtracker and Meddevicetracker 87
Bioresearch Monitoring (BIMO) 134
blogs and news sites, for surveillance and monitoring 48

### C

Canada, FOI requests in 108
- filing complaints 109–110
- fulfillment of request 109–110
- information available with 108–110
- laws governing 107
- submission of request 108–110
- timeline for response 108–110
China Food and Drug Administration (CFDA). See National Medical Products Administration (NMPA)
Citeline 88
Code of Federal Regulations (CFR) 94
- commenting on regulatory documents 169
- benefits of 169–172, 170–172
- company goals for 170
- direct or indirect commenting 169–172, 171–172
- KPI for RI performance 163
- locating items for 169–172
- planning with regulatory agenda 171–172
- purpose of 169
- using subject matter experts for 171–172
- comment period
  - Federal Register publication and 95
  - length of 172
  - review of comments 172
communication skills for RI professional 27–31
company size
- outsourcing and 38–39
RI requirements for 37–39
surveillance for 47
core investment
  basic cost of setting up RI department 37
  purchase of tools 37–39
  RI output and tool costs 43
  RI services and KPIs for 161–164
Cortellis Regulatory Intelligence™ and IQVIA 84
  curation and annotation of data 182
D
  databases for regulatory intelligence 81. See also toolbox for regulatory intelligence
    AdisInsight 89–92
    Biomedtracker and Meddevicetracker 87–92
    Bioresearch Monitoring (BIMO) 134
    categories of 81–92
    Citeline 88–92
    clinical trial registries 84
    Cortellis Regulatory Intelligence™ and IQVIA 84
    defined 81
    Doctor Evidence DOC Label™ and Reed Tech Navigator™ for Drug Labels 87
    fee-free health authority databases 83–84
    for inspection tracking and trends 134
    for regulations/guidance outside US 96
    information contained in 81–92
PharmaPendium® 86
  PharmaPendium® Features 87
  public (free) database 82–92
Reed Tech Navigator™ for Drug Labels and Doctor Evidence DOC Label™ 86
  search functionality of 82
  subscription database and search functions of 82
  summary of uses of RI databases 90
  data ingestion 182
  data mining and predictive analytics 180
  Deep Learning 180
  disease specific regulatory analysis 180
  distribution of regulatory intelligence 157.
  See newsletters
  regulatory intelligence newsletters 157–160
Docket 95
  documentation for regulatory research 60
Drug Information Association (DIA) 62
due diligence
  acquisition of pharmaceutical asset 151, 145–152
  documents required for analysis 146–152
  due diligence defined 141–152
  for healthcare product 143–152
public information sources for 147–152
RI role in 141, 143–152
timeline requirements for 145–152
E
  education for work in RI 24
EMA committee profiles
  Oral Explanation committee 117–124
  resources for 120
  Scientific Advice Working Party 118
  Scientific Advisory Groups 117–124
EU, access-to-documents requests in 105–110
  appeal of request denial 105
  information available through 105–110
  processing of request 105–110
  submission process 105–110
EudraLex comment notices 172
European Medicines Agency (EMA)
databases from 83
  downloadable Excel trackers 83
  high-stakes meeting participants 116
  organizational structure 9
  overview of 9
  participant profiles for meetings with 116–124
European Union Regulatory Intelligence Network Group (EU RING) 2
experience for work in RI
  health authority interactions 24
  industry experience 24
external databases for RI 82
F
FDA reviewer profiles 125
  areas of special interest for 128
  background information sources 126
  categories of reviewers 125–128
IND and NDA/BLA reviewer information sources 126–128
  information collection and use of 125–126
  presentation to regulatory team 128
  profile collection example 127
  sources for names of 126
FDLI SmartBrief 48
federal dockets management system (FDMS) 95
Federal Register
  content and schedule for 94
  guidance documents in 95
  in creation of regulations 94
  final rule stage, preparation and publication of 95
five Ws and the H of RI 1
Food and Drug Administration (FDA)
  briefing package 116
databases from 83
  organizational structure of 7
  overview 7
Freedom of Information (FOI) request
  in Australia 106–110
  in Canada 107–110
  in EU 105
  KPI for RI performance 162
  overview of 101
  use in RI 101–110

G
Google services 42
  Google Alerts for surveillance and monitoring 49
  Google Translate 49
  searches using 42

H
hard skills for RI professional 24–31
health authority interactions/meetings
  experience for work in RI 24–31
  mock meetings for EMA and FDA 119–124
  participant profiling for 111
  RI support for 175
Health Canada
  drug and devices approved by 67
  organization of 7
  overview 7
healthcare product regulatory due diligence
  clinical program status 144–152
  commercial potential of 144
  competitive product intelligence 144–152
  manufacturing process 143–152
  nonclinical studies 143–152
  product patent status 144–152
  regulatory strategy assessment 144

I
industry experience for work in RI 24
informal rulemaking 94
information and intelligence distinction 2
information sources for regulatory intelligence
  Federal Register 94
  free and subscription-based 41–42
  Google searches for 42
  networking for 42
inspection tracking 129
  benefits and limitation of RI for 131–140
  EU resources for 134–140
  FDA databases for 134
  global/international resources 135–140
  purpose of 129–140
  purpose of inspections 129
  reasons for intelligence on 129–140
  research plan for 133–140
  stages of product development and 130
  types of citations issued 133
  use of agency databases for 133–140
  US resources 134–140
inspector profiles
  information collected for 136–140
  resources for 137
internal databases, private-domain information
  in 81
International Council for Harmonization (ICH) 181
International Medical Device Regulators Forum (IMDRF) 181
intranet/SharePoint site
  content of 38
  intelligence presentation format for 58

K
Key Performance Indicators (KPIs) for RI success 161
knowledge management 38–39

L
large-company RI surveillance 47
leadership in RI 28–31
lemmatization 183
lifecycle management, RI role in 3

M
Machine Learning (ML) 180
marketing approval, RI role in 3
Medicines and Healthcare Products Regulatory Agency (MHRA)
  organizational structure 9–13
  overview 9
Mention for surveillance/monitoring 49
metrics for RI success 161
ad hoc requests (includes precedent analysis)
162–164
commenting on draft documents 163–164
customer satisfaction 162–164
external presentations at conferences 163–164
Freedom of Information request ss 162–164
identification of regulatory trends 163–164
internal presentations (knowledge management) 163–164
intranet site maintenance 161
news briefs/newsletters production 161
professional association involvement 164
regulatory development strategy plan contributions 162–164
services and KPIs for 161–164
trade association and consortia participation 164
white or reflection papers development 163–164
monitoring. See surveillance and monitoring

N
named entity recognition 183
National Medical Products Administration (NMPA) 11
organizational structure of 12
overview 11
natural language processing (NLP) 180
networking, as information source 42
newsletters
audience and schedule for 157
design and content 158
design and content of 158–159
distribution tools for 157–160
in-house or vendor creation of 159
KPI of RI performance 161
measuring success of 159

O
Office of Information and Regulatory Affairs 95–96
ongoing surveillance 47
outsourcing, company size and 38–39

P
participant profiling
EMA committee members 116
FDA reviewers 125
for good communication 111–124
for health authority meetings 111
inspector profiles 129
profile content 112–124
recruiting/conducting mock meetings 119–124
using profiles 112–124
part of speech tagging 183
periodic surveillance 47
Pharmaceuticals and Medical Devices Agency (PMDA)
organizational structure of 11
overview 11
PharmaPendium 86, 126
playbook format
for strategy documentation 18
role in strategy development 20
product classification, global variation in 2
professional associations 61
benefits of membership 61
regional regulatory associations 62
RI involvement in 164
trade associations vs. 61
proposed rules 94–96
publication surveillance and monitoring 48
public sources
AI techniques for monitoring 183
for regulatory precedent 63

R
Really Simple Syndication. See RSS feeds
Reed Tech Navigator™ for Drug Labels and Doctor Evidence DOC Label™ 86
regulation and guidance documents in US 93
Federal Register 94
Code of Federal Regulations (CFR) 94
for English-speaking countries/regions 93
guidances/guidelines in other countries/regions 96
legislative and regulation development process 93
process for creation of regulations 94–95
Regulatory Affairs Professionals Society (RAPS)
history and benefits from 61
news letters for surveillance and monitoring 48
regulatory agencies
e-mail subscriptions to 48
functions of 12
history and organization of 7
overview of 8
regulatory agenda, importance in planning strategy 95
regulatory extrapolation from other diseases 181
regulatory intelligence professionals
activities of 37–39, 45
background and skills of 23
creating actionable intelligence 5–6
in strategies that lack precedent 176
internal services of 33–39
knowledge of available tools 43
role in regulatory and R&D 177
service to team members 5
skills needed by 4–6
regulatory intelligence (RI)
as a separate department 5, 33
background and skills for 23–24
conduct of 4
core investigative questions in 1
creating intelligence 58–60
data bases for 81
disease-specific regulatory intelligence a
alysis 176
distribution 157
division of activities in 4–6
FOI request use in 101
format for core team/product development
team 58
growth of 179
implementation of 4
management and storage of 38
measuring success of 161
need for dedicated RI function 33
outsourcing of 38
product approval and sustainability 3
regulations and guidance role in 96
role in due diligence 141
small and large company needs 39
sources for regulatory precedent 63
strategy preparation 3
toolbox for 3
tracking regulatory landscape changes for 45–51
use of artificial intelligence in 179
use of white papers 97–100
regulatory policy 165
defined 165–167
responsibilities and function of 165–167
role in organization 167
regulatory precedent, public sources for 63
importance and use of precedent 63–64
in strategy development 3
postapproval precedent
approved labeling 75
lifecycle information and supplements/
variations 78
postmarketing requirements and
commitments 77–79
product data exclusivity 79
review summaries and approval packages 72–74
preapproval precedent 65
Advisory Committees/Advisory Groups 69
clinical trial databases registries 71
drug and medical device highlights in
Canada 67
expedited pathways and their designations 67
orphan medicines 69
pediatric investigation 70
scientific advice 66
regulatory strategy 15
comprehensive development plan in 21
contributors to 17, 16–21
definition 15
documentation for 16–21
goals of 3
high-level strategy output examples 19
implementation of 16–21
importance of precedents in 63
management and updates of 20
measures of success 21
monitoring and surveillance in 45
playbook format for 18
purpose of 15–21
questions to be addressed in 18
reasons for documentation 18
regulatory agency perspectives on 20–21
regulatory agenda for planning 95
scope of 15–21
sources of change in 20–21
regulatory strategy development 173
for drug development and lifecycle
management 173–177
RI for strategies that lack precedent 176–177
strategic value provided by RI professionals
173–177
relationship extraction by AI 183
research process 53. See also surveillance and
monitoring
checklist for clinical searches 55
conducting search and compiling
information 56–58
data collection/presentation format for 57
Index

defining key search terms 54–60
department specific research 60
information mining 4
overview of 53
sample output from 59
starting locations for search 56
subscription databases for 83–84
typical topics for 53
understand and refining the question 54
use of FOI in 109
uses of RI databases 90
return on investment (ROI) demonstration 37
Rich Site Summary. See RSS feeds
Robotic Process Automation (RPA) 180
RSS feeds 49
RSS feeds, for surveillance and monitoring 49

S
self-motivation 30–31
setting up an RI department
activities of 33
assessing success of 161–164
benefits of 36
company size consideration for 37–39
dedicated staff for 35
demonstrating the value of 35–39
establishing a competitive edge 4
factors to consider in 36, 39
investment in 34–39
minimum requirements for 35
steps in 34
subscription database evaluation 91
skill set for RI professional 23
small-company RI surveillance 47
soft skills for RI professional 25–29
stakeholders
communication of work to 37
engagement with RI department 34
strategic and critical thinking in RI 26–31
strategy development
RI professional’s role in 4
tracking regulations and guidance for 96
surveillance and monitoring 45, 53. See also research process
Federal Register for 94
data mining and predictive analytics 180
defined 45
determining intervals for 47–48
fee/subscription tools for 50–51
for product compliance 4
for strategy development 176
free tools for 48–51
outcomes of 46
regulatory landscape 4
topics for 46
tracking regulations and guidance 96
Swissmedic
organization of 9
overview of 9

T
Talkwalker Alerts for surveillance/monitoring 49
Target Product Profile (TPP)
in regulatory strategy 16
in strategy document 18
KPIs for strategy development 162
teaching and educational forums 153
common topics covered 153–155
KPI for RI performance 162
non-RI regulatory professionals and 155–156
The Organization for Professionals in Regulatory Affairs (TOPRA) 62
Therapeutic Goods Administration (TGA)
FOI requests to 106–110
organizational structure of 9
overview of 9–13
tokenization 183
toolbox for regulatory intelligence 41. See also databases for regulatory intelligence
free and subscription-based tools for 41
information sources 4
purchase of 37–39
regulatory agency feeds 48
subscription/fee tools 50
trade associations 166–167

U
United States, FOI request in
appeals of denial 104–110
disclosure exemptions for 101–110
exemptions and exclusions 102
information available with 101–110
information not available with 102–110
online submission of 103
physical requests for 103
processing of submission 103
requester’s information for 103
response timeline 104
service fees for 104
use of vendors for 104–110

W

white papers 97
examples of 100
for the specific audience 98–100
KPI for RI performance 163
length of 98
other white paper resources 99
purposes of 97
regulatory authority examples 99
standard format for 98–100
use in RI 97
World Health Organization (WHO) 181